Skip to main content
. 2021 Jun 1;22(10):1658–1670. doi: 10.3348/kjr.2020.1117

Table 3. Tumor Response and Clinical Situation at the Time of the Tumor Response Assessment Protocol Termination in 127 Patients.

Tumor Response Overall CR PR SD Non-PD PD
All 127 9 (7.1) 33 (26.0) 3 (2.4) 45 (35.4) 82 (64.6)
Death 3 (2.4) 2 (22.2) 1 (3.0) 3 (6.7)
Follow-up loss or transfer 20 (15.7) 3 (33.3) 8 (24.2) 1 (33.3) 12 (26.7) 8 (9.8)
Other treatment 104 (81.9) 4 (44.4) 24 (72.7) 2 (66.7) 30 (66.7) 74 (90.2)
Conventional chemoembolization 66 (52.0) 1 (11.1) 12 (36.4) 1 (33.3) 14 (31.1) 52 (63.4)
+ Combination treatment 4 (3.1) 1 (11.1) 1 (3.0) 2 (4.4) 2 (2.4)
Radiofrequency ablation 23 (18.1) 1 (11.1) 9 (27.3) 10 (22.2) 13 (15.9)
Percutaneous ethanol injection 6 (4.7) 2 (6.1) 2 (4.4) 4 (4.9)
Liver transplantation 4 (3.2) 1 (11.1) 1 (2.2) 3 (3.7)
Resection 3 (2.4) 1 (11.1) 1 (3.0) 1 (33.3) 3 (6.7)
Intraarterial chemotherapy 2 (1.6) 2 (2.4)

Values are number of patients with the percentage in parentheses. CR = complete response, PD = progressive disease, PR = partial response, SD = stable disease